Fidelity International
FOLD

Fidelity International’s Amicus Therapeutics FOLD Stock Holding History

Fidelity International’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$182M Buy
12,560,028
+11,603,028
+1,212% +$166M 0.14% 160
2025
Q4 		$13.6M Buy
+957,000
New +$9.4M 0.01% 537

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Fidelity International's FOLD Position: Q1 2026 in Review

Fidelity International increased its Amicus Therapeutics (FOLD) stake by 1,212% in Q1 2026, buying an estimated $166M and bringing the position to 12,560,028 shares worth $182M. The position accounts for 0.14% of the portfolio, ranked #160.

Fidelity International first reported a position in FOLD in Q4 2025 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Fidelity International held 12,560,028 shares of Amicus Therapeutics worth $182M as of Q1 2026.
  • Fidelity International bought 11,603,028 Amicus Therapeutics shares in Q1 2026, an estimated $166M.
  • Amicus Therapeutics made up 0.14% of Fidelity International's portfolio in Q1 2026, its #160 holding.
  • Fidelity International first reported a position in Amicus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Fidelity International's 13F filing for Q1 2026, filed 15 May 2026.